These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 32408853)

  • 1. Six-month results of stenting of the femoropopliteal artery and predictive value of interleukin-6: Comparison with high-sensitivity C-reactive protein.
    Guo S; Zhang Z; Wang L; Yuan L; Bao J; Zhou J; Jing Z
    Vascular; 2020 Dec; 28(6):715-721. PubMed ID: 32408853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PEACE I all-comers registry: patency evaluation after implantation of the 4-French Pulsar-18 self-expanding nitinol stent in femoropopliteal lesions.
    Lichtenberg M; Kolks O; Hailer B; Stahlhoff WF; Tiefenbacher C; Nolte-Ernsting C; Arjumand J; Wittenberg G
    J Endovasc Ther; 2014 Jun; 21(3):373-80. PubMed ID: 24915584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of IVUS-Derived Vessel Size on Midterm Outcomes After Stent Implantation in Femoropopliteal Lesions.
    Miki K; Fujii K; Tanaka T; Yanaka K; Yoshihara N; Nishimura M; Sumiyoshi A; Horimatsu T; Imanaka T; Fukunaga M; Akahori H; Masuyama T; Ishihara M
    J Endovasc Ther; 2020 Feb; 27(1):77-85. PubMed ID: 31948376
    [No Abstract]   [Full Text] [Related]  

  • 4. Paclitaxel-Eluting Balloon Versus Standard Balloon Angioplasty in In-Stent Restenosis of the Superficial Femoral and Proximal Popliteal Artery: 1-Year Results of the PACUBA Trial.
    Kinstner CM; Lammer J; Willfort-Ehringer A; Matzek W; Gschwandtner M; Javor D; Funovics M; Schoder M; Koppensteiner R; Loewe C; Ristl R; Wolf F
    JACC Cardiovasc Interv; 2016 Jul; 9(13):1386-92. PubMed ID: 27388828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PTA and Stenting of Femoropopliteal Trunk With Cordis Smartflex Stent System: A Single-Center Experience.
    Garriboli L; Miccoli T; Pruner G; Jannello AM
    Vasc Endovascular Surg; 2020 Jan; 54(1):17-24. PubMed ID: 31526118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of restenosis in the use of helical interwoven nitinol stents to treat femoropopliteal occlusive disease.
    Chan YC; Cheng SW; Cheung GC
    J Vasc Surg; 2015 Nov; 62(5):1201-9. PubMed ID: 26169015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence and the clinical impact of stent fractures after primary stenting for TASC C and D femoropopliteal lesions at 1 year.
    Davaine JM; Quérat J; Guyomarch B; Brennan MÁ; Costargent A; Chaillou P; Patra P; Gouëffic Y
    Eur J Vasc Endovasc Surg; 2013 Aug; 46(2):201-12. PubMed ID: 23773773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Plaque Calcification and Stent Oversizing on Clinical Outcomes of Atherosclerotic Femoropopliteal Arterial Occlusive Disease Following Stent Angioplasty.
    He HP; Weng JC; Zhao Y; Cai SH; Zhang XL; Yin HH
    Eur J Vasc Endovasc Surg; 2019 Aug; 58(2):215-222. PubMed ID: 30862415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug-Eluting Stent vs Percutaneous Transluminal Angioplasty for Treatment of Femoropopliteal In-Stent Restenosis: Results From a Retrospective 1-Year Multicenter Study.
    Murata N; Takahara M; Soga Y; Nakano M; Yamauchi Y; Zen K; Kawasaki D; Yokoi H; Tosaka A; Tanaka N; Iida O
    J Endovasc Ther; 2016 Aug; 23(4):642-7. PubMed ID: 27099284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravascular ultrasound measurements after drug-eluting stent placement in femoropopliteal lesions: determining predictors of restenosis.
    Mori S; Hirano K; Nakano M; Muramatsu T; Tsukahara R; Ito Y; Ishimori H
    J Endovasc Ther; 2015 Jun; 22(3):341-9. PubMed ID: 25862363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcomes of balloon angioplasty alone versus nitinol stent implantation in patients with small femoropopliteal artery disease: Observations from the Retrospective Multicenter Analysis for Femoropopliteal Stenting (REAL-FP).
    Kamioka N; Soga Y; Kuramitsu S; Iida O; Hirano K; Suzuki K; Kawasaki D; Yamaoka T; Suematsu N; Shintani Y; Miyashita Y; Takahashi H; Tsuchiya T; Shinozaki N; Okazaki S; Ando K
    Catheter Cardiovasc Interv; 2017 Nov; 90(5):790-797. PubMed ID: 28722294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meta-Analysis-Derived Benchmarks of Patency and Target Lesion Revascularization of Percutaneous Balloon Angioplasty from Prospective Clinical Trials of Symptomatic Femoropopliteal In-Stent Restenosis.
    Shammas NW; Jones-Miller S; Lemke J
    J Vasc Interv Radiol; 2016 Aug; 27(8):1195-203. PubMed ID: 27350033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preoperative inflammatory status as a predictor of primary patency after femoropopliteal stent implantation.
    Nakazawa KR; Wengerter SP; Power JR; Lookstein RA; Tadros RO; Ting W; Faries PL; Vouyouka AG
    J Vasc Surg; 2017 Jul; 66(1):151-159. PubMed ID: 28259571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient-level meta-analysis of 999 claudicants undergoing primary femoropopliteal nitinol stent implantation.
    Rocha-Singh KJ; Beckman JA; Ansel G; Lyden SP; Schneider P; Mehta M; Dake M; Mullin CM; Jaff MR;
    Catheter Cardiovasc Interv; 2017 Jun; 89(7):1250-1256. PubMed ID: 28303688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Laser atherectomy and drug-coated balloons for the treatment of femoropopliteal in-stent restenosis: 2-Year outcomes.
    Kokkinidis DG; Behan S; Jawaid O; Hossain P; Giannopoulos S; Singh GD; Laird JR; Valle JA; Waldo SW; Armstrong EJ
    Catheter Cardiovasc Interv; 2020 Feb; 95(3):439-446. PubMed ID: 31816169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination therapy of heparin-bonded covered stent and bare-nitinol stent assessed by intravascular ultrasound.
    Katsuki T; Tomoi Y; Yamaji K; Soga Y; Imada K; Ito N; Hiramori S; Ando K
    Heart Vessels; 2020 Nov; 35(11):1502-1509. PubMed ID: 32462463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug-eluting stenting for femoropopliteal lesions, followed by cilostazol treatment, reduces stent restenosis in patients with symptomatic peripheral artery disease.
    Zen K; Takahara M; Iida O; Soga Y; Kawasaki D; Nanto S; Yokoi H; Matoba S;
    J Vasc Surg; 2017 Mar; 65(3):720-725. PubMed ID: 28073668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiographic characteristics of femoropopliteal in-stent restenosis: association with long-term outcomes after endovascular intervention.
    Armstrong EJ; Singh S; Singh GD; Yeo KK; Ludder S; Westin G; Anderson D; Dawson DL; Pevec WC; Laird JR
    Catheter Cardiovasc Interv; 2013 Dec; 82(7):1168-74. PubMed ID: 23630047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Twelve-month experience with the GORE® TIGRIS® Vascular Stent in the superficial femoral and popliteal arteries.
    Piorkowski M; Freitas B; Steiner S; Botsios S; Bausback Y; Scheinert D; Schmidt A
    J Cardiovasc Surg (Torino); 2015 Feb; 56(1):89-95. PubMed ID: 25410147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences in Intravascular Ultrasound Measurement Values Between Treatment Modalities for Restenosis in Femoropopliteal Lesions.
    Aihara H; Higashitani M; Takimura H; Tobita K; Jujo K; Hozawa K; Yamaguchi T; Iwata Y; Tokuyama H; Sakurai M; Murata N; Fujimoto Y; Kikuchi A; Koganei H; Sato A; Noguchi Y; Ieda M
    Circ J; 2020 Jul; 84(8):1320-1329. PubMed ID: 32581151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.